Safety and effectiveness of direct oral anticoagulants versus warfarin in chronic kidney disease and atrial fibrillation: scoping review

Introduction: Anticoagulation in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) represents a clinical challenge due to the simultaneous increase in thromboembolic and bleeding risks. Although direct oral anticoagulants (DOACs) have demonstrated favorable safety and effectiveness profiles compared with warfarin in the general population with AF, the evidence in patients with impaired renal function is heterogeneous, especially in advanced stages and in those receiving renal replacement therapy. Objective: To map and characterize the available scientific evidence on the safety and effectiveness of direct oral anticoagulants versus warfarin in adult patients with chronic kidney disease and atrial fibrillation, considering different stages of renal function, treatments, and clinical outcomes Methods: A scoping review will be conducted following the Joanna Briggs Institute (JBI) methodology and PRISMA-ScR recommendations. The literature search was conducted on November 9, 2026, in PubMed/MEDLINE, Scopus, and Web of Science, considering publications between January 2015 and November 2026. Comparative studies in adults with nonvalvular AF and CKD stages G1–G5, including patients on dialysis, will be included. Study selection will be carried out by independent reviewers using RAYYAN. Data will be extracted into Microsoft Excel and analyzed descriptively and thematically by CKD stage, DOAC used, dose, and safety and effectiveness outcomes. Expected results: Heterogeneous evidence is expected regarding comparisons of apixaban, rivaroxaban, edoxaban, and dabigatran versus warfarin, with differences in methodological designs, populations, and outcomes assessed. Lower representation of patients with advanced CKD and those on dialysis is anticipated, as is uncertainty about dosage regimens and clinical outcomes in these subgroups. The findings will help identify knowledge gaps and guide future research. Descriptors (MeSH): Atrial Fibrillation; Renal Insufficiency, Chronic; Anticoagulants; Warfarin; Stroke; Hemorrhage. Keywords: atrial fibrillation; chronic kidney disease; direct oral anticoagulants; warfarin; safety; effectiveness; scoping review.

Authors

Publication Details

Journal
Open Science Framework
Published
2026-11-12
DOI
https://doi.org/10.17605/osf.io/qbg7r
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Safety and effectiveness of direct oral anticoagulants versus warfarin in chronic kidney disease and atrial fibrillation: scoping review

María Paula Vásquez Bazurto
Open Science Framework
Atrial Fibrillation Management and Outcomes
article

Safety and effectiveness of direct oral anticoagulants versus warfarin in chronic kidney disease and atrial fibrillation: scoping review

María Paula Vásquez Bazurto
article en

Abstract

Introduction: Anticoagulation in patients with atrial fibrillation (AF) and chronic kidney disease (CKD) represents a clinical challenge due to the simultaneous increase in thromboembolic and bleeding risks. Although direct oral anticoagulants (DOACs) have demonstrated favorable safety and effectiveness profiles compared with warfarin in the general population with AF, the evidence in patients with impaired renal function is heterogeneous, especially in advanced stages and in those receiving renal replacement therapy. Objective: To map and characterize the available scientific evidence on the safety and effectiveness of direct oral anticoagulants versus warfarin in adult patients with chronic kidney disease and atrial fibrillation, considering different stages of renal function, treatments, and clinical outcomes Methods: A scoping review will be conducted following the Joanna Briggs Institute (JBI) methodology and PRISMA-ScR recommendations. The literature search was conducted on November 9, 2026, in PubMed/MEDLINE, Scopus, and Web of Science, considering publications between January 2015 and November 2026. Comparative studies in adults with nonvalvular AF and CKD stages G1–G5, including patients on dialysis, will be included. Study selection will be carried out by independent reviewers using RAYYAN. Data will be extracted into Microsoft Excel and analyzed descriptively and thematically by CKD stage, DOAC used, dose, and safety and effectiveness outcomes. Expected results: Heterogeneous evidence is expected regarding comparisons of apixaban, rivaroxaban, edoxaban, and dabigatran versus warfarin, with differences in methodological designs, populations, and outcomes assessed. Lower representation of patients with advanced CKD and those on dialysis is anticipated, as is uncertainty about dosage regimens and clinical outcomes in these subgroups. The findings will help identify knowledge gaps and guide future research. Descriptors (MeSH): Atrial Fibrillation; Renal Insufficiency, Chronic; Anticoagulants; Warfarin; Stroke; Hemorrhage. Keywords: atrial fibrillation; chronic kidney disease; direct oral anticoagulants; warfarin; safety; effectiveness; scoping review.

Open Science Framework
Good health and well-being
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon